<DOC>
	<DOCNO>NCT00036023</DOCNO>
	<brief_summary>Chemotherapy often cause anemia patient cancer . Anemia low number red blood cell . The symptom anemia may include fatigue , dizziness , headache , chest pain , shortness breath . Erythropoietin hormone make kidney signal bone marrow produce red blood cell . Recombinant human erythropoietin produce laboratory effect hormone produce body . Use recombinant human erythropoietin allow body produce red blood cell , possibly eliminate decrease symptom need red blood cell transfusion . Recombinant human erythropoietin FDA approve treat anemia cancer patient receive chemotherapy . This clinical study investigate effectiveness darbepoetin alfa treatment anemia patient non-myeloid malignancy receive chemotherapy every three week . Darbepoetin alfa recombinant erythropoietic protein stimulate production red blood cell . This medication approve treat cancer patient anemia , however approve FDA treat chronic renal failure patient anemia .</brief_summary>
	<brief_title>Chemotherapy Related Anemia Patients With Non-Myeloid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Patients nonmyeloid malignancy * Patients receive least 12 week chemotherapy 3week cycle schedule * Patients anemia ( hgb &gt; /= 9.0 &lt; /= 11.0 g/dL )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>